Key Drivers
- Margin Expansion
- Strong Cashflow
- High Leverage
AIAI Summary
OGN is now a leveraged recovery trade rather than a distressed-value bargain: improving margins and strong free cash flow support deleveraging, but the rerated share price leaves limited room for setbacks unless women's-health catalysts—especially MIUDELLA—translate into durable growth. Investors should prioritize evidence of debt reduction and sustained cash generation, as $8.55B of debt and ~2.7x interest coverage make execution or pricing disappointments disproportionately damaging.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Strong Cashflow
- •High Leverage
OGN shows improving margins, cash flow, and liquidity, but high leverage and thin interest coverage warrant caution despite a moderate 17x P/E.
Price Behavior
Key Price Behavior Insights:
- •Oversold momentum
- •Support holding
- •Resistance overhead
OGN is mildly bearish last month but oversold near $13.63–$13.65 support, with a rebound requiring a break above $13.75–$13.78.
Rebounded toward $13.69 after declining from $13.78
Sentiment & News
Key News Insights:
- •FDA application
- •Mixed institutions
- •Ticker confusion
Organon's FDA filing for extended MIUDELLA use and mixed institutional flows may support attention, while Orogen ticker-related headlines are unrelated.
The FDA review is the clearest potential positive catalyst for Organon, though investor activity remains mixed
Similar Companies in Healthcare
Other companies in the same sector with AI ratings